Belite Bio (BLTE) Other Non Operating Income (2024 - 2026)

Belite Bio (BLTE) posted quarterly Other Non Operating Income of -$417000.0 for Q4 2025, down 406.62% year-over-year from $136000.0 in Q4 2024, and down 406.62% quarter-over-quarter from $136000.0 in Q4 2024.

Belite Bio (BLTE) Other Non Operating Income (2024 - 2026) Analysis & Trends

Belite Bio's Other Non Operating Income history runs 2 years deep, the most recent figure standing at -$417000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Belite Bio 6.40 Bn 6.40 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -13.20 Mn
Dec 31, 2025 -417,000.00
Dec 31, 2024 136,000.00